Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alexion Pharmaceuticals Inc. ALXN

Healthcare Biotechnology
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS... see more

Recent & Breaking News (NDAQ:ALXN)

New Long-Term Data Presented at WCPGHAN 2016 Show Rapid and Sustained Improvements in Important Markers of Liver Injury and Lipid Abnormalities in Children and Adults with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma® (sebelipase alfa)

Business Wire October 6, 2016

The Market In 5 Minutes: A Three-Decade Low For The Pound

Benzinga.com  October 4, 2016

Les employés d'Alexion font du bénévolat ensemble pour la première Journée mondiale de service célébrée par l'entreprise

Business Wire September 23, 2016

Alexion Employees Volunteer Together in Company’s First Global Day of Service

Business Wire September 23, 2016

Alexion Launches Uncommon Strength Campaign to Unite and Celebrate the Courage and Resilience of People Living with Rare Diseases

Business Wire September 13, 2016

Alexion to Present at Upcoming Investor Conferences

Business Wire September 6, 2016

La Commission européenne accorde la désignation de médicament orphelin à l'ALXN1007 pour le traitement de patients atteints de la réaction du greffon contre l'hôte (GVHD)

Business Wire August 30, 2016

European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)

Business Wire August 29, 2016

Alexion Reports Second Quarter 2016 Results

Business Wire July 28, 2016

Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients with Mucopolysaccharidosis IIIB (MPS IIIB)

Business Wire July 14, 2016

Alexion Pharmaceuticals to Report Second Quarter 2016 Results on Thursday, July 28, 2016

Business Wire July 11, 2016

New Data from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG) Presented at ICNMD Annual Congress

Business Wire July 7, 2016

SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm

Business Wire June 17, 2016

Présentation de données de dernière minute au congrès de l’AEH : Tous les patients atteints de HPN traités avec une dose d’ALXN1210 administrée mensuellement dans le cadre d’une étude de phase 1/2 affichent des réductions rapides et soutenues de la LDH

Business Wire June 11, 2016

Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH

Business Wire June 10, 2016

Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics

PR Newswire June 9, 2016

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN)

PR Newswire June 8, 2016

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims Against Alexion Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm

Business Wire June 7, 2016

Alexion Closed Down 10%; Piper Says 'Buy On Weakness'

Benzinga.com  June 7, 2016

Barclays Cuts Alexion Pharmaceuticals Target From $180 To $165

Benzinga.com  June 7, 2016